Further investigations are warranted to explore the interactions between METS-IR and other metabolic biomarkers (e.g., fasting insulin, FFAs, leptin, adiponectin) to clarify the mechanistic pathways of insulin resistance in NAFLD pathogenesis. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.